Finnish startup AIATELLA has raised €2m ($2.27m) in financing to develop and scale its cardiovascular imaging technology powered by AI.
The investment will support the company in conducting clinical trials and further developing its ultrasound-based preventative screening tool, which can identify and quantify carotid artery narrowing within minutes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Nordic Science Investments spearheaded the funding round, with contributions from Specialist VC, Business Finland, and Harjavalta Ventures, among other investors.
The Automated Image Measurement technology of the startup leverages images from ultrasound, computed tomography, and magnetic resonance imaging to analyse vascular imaging.
This multimodal technology identifies abnormalities and quantifies changes over time in those at risk.
It significantly reduces the time specialists spend on manual image measurements and documentation. As a result, clinicians can dedicate more time to patient care.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAIATELLA is currently navigating the medical approval processes in several European and North American countries, including France, the US, and the UK.
AIATELLA co-founder and CEO Jack Parker said: “Our technology helps medical professionals analyse imaging much more efficiently, and at an earlier stage, so patients can get help before it’s too late.”
Initially applied to the aorta artery, AIATELLA’s vision extends to encompass all blood vessels in the body with its technology.
The startup noted that it is also developing a portable ultrasound-based screening technology for mass screening of individuals prior to the occurrence of symptoms.
This approach aims to facilitate early detection of cardiovascular diseases, which are a major cause of mortality worldwide.
The technology has already been employed in the UK and Finland at screening events, where it has helped identify potentially at-risk individuals.
AIATELLA also aims to gather data on the presentation and progression of cardiovascular conditions across different sexes and ethnicities, as symptoms can vary widely among these different groups.
